Literature DB >> 26722541

Genetic association between PIK3CA gene and oral squamous cell carcinoma: a case control study conducted in Chongqing, China.

Xiaoxiao Wan1, Xian Li1, Junyan Yang2, Wei Lv2, Qiming Wang2, Ying Chen2, Yong Li1.   

Abstract

PIK3CA has been shown to be involved in many malignant tumors. This study was designed to determine the expression level of PIK3CA in oral squamous cell carcinoma (OSCC) and the association of gene polymorphisms of PIK3CA with OSCC in Chinese population. The expression of PIK3CA was detected by real-time PCR in tumor and pericarcinomatous tissues of 10 OSCC patients. Nine single-nucleotide polymorphisms (SNPs) of PIK3CA (rs1607237, rs17849079, rs2677764, rs2699887, rs4855094, rs4975596, rs6443624, rs7651265 and rs7736074) in blood of 113 OSCC patients and 184 normal controls were genotyped using matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) assay. The gene expression of PIK3CA was significantly higher in tumor tissues of OSCC patients than that in pericarcinomatous tissues (P = 0.012). An increased frequency of the C allele of PIK3CA rs1607237 was observed in OSCC patients as compared with controls; However, the significance was lost after Bonferroni correction (P = 0.048, pc = 0.576). In further stratification analysis, although the frequencies of PIK3CA rs4975596 A allele in male patients and rs1607237 C allele in female patients were increased (P = 0.032, P = 0.020, respectively), the significance was also missing when Bonferroni correction was performed (P c = 0.384, (P c = 0.24, respectively). The prevalence of other SNPs of PIK3CA did not differ between OSCC patients and controls. The expression of PIK3CA was increased in OSCC tumors; however, none of the nine tested SNPs of PIK3CA was associated with susceptibility to OSCC in the studied population.

Entities:  

Keywords:  MALDI-TOF MS; Oral squamous cell carcinoma; PIK3CA; RT-PCR; gene expression; single nucleotide polymorphisms

Mesh:

Substances:

Year:  2015        PMID: 26722541      PMCID: PMC4680486     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  27 in total

1.  Association of expression aberrances and genetic polymorphisms of lysyl oxidase with areca-associated oral tumorigenesis.

Authors:  Tzong-Ming Shieh; Shu-Chun Lin; Chung-Ji Liu; Shu-Shin Chang; Ti-Hsuan Ku; Kuo-Wei Chang
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

2.  Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma.

Authors:  Ichiro Akagi; Masao Miyashita; Hiroshi Makino; Tsutomu Nomura; Nobutoshi Hagiwara; Ken Takahashi; Kazumitsu Cho; Takuya Mishima; Osamu Ishibashi; Toshikazu Ushijima; Toshihiro Takizawa; Takashi Tajiri
Journal:  Int J Oncol       Date:  2009-03       Impact factor: 5.650

3.  Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors.

Authors:  Goodarz Danaei; Stephen Vander Hoorn; Alan D Lopez; Christopher J L Murray; Majid Ezzati
Journal:  Lancet       Date:  2005-11-19       Impact factor: 79.321

4.  Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.

Authors:  Martha L Slattery; Jennifer S Herrick; Abbie Lundgreen; Francis A Fitzpatrick; Karen Curtin; Roger K Wolff
Journal:  Carcinogenesis       Date:  2010-07-09       Impact factor: 4.944

5.  PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.

Authors:  Xia Pu; Michelle A T Hildebrandt; Charles Lu; Jie Lin; David J Stewart; Yuanqing Ye; Jian Gu; Margaret R Spitz; Xifeng Wu
Journal:  Lung Cancer       Date:  2010-05-05       Impact factor: 5.705

6.  PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma.

Authors:  Feifei Wen; Shuang He; Chenbo Sun; Tangyue Li; Shuhua Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

7.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

Review 8.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

9.  Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study.

Authors:  Michael Rivera; Julio Ricarte-Filho; Snehal Patel; Michael Tuttle; Ashok Shaha; Jatin P Shah; James A Fagin; Ronald A Ghossein
Journal:  Hum Pathol       Date:  2009-11-13       Impact factor: 3.466

10.  Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study.

Authors:  James V Lacey; Hannah Yang; Mia M Gaudet; Alison Dunning; Jolanta Lissowska; Mark E Sherman; Beata Peplonska; Louise A Brinton; Catherine S Healey; Shahana Ahmed; Paul Pharoah; Douglas Easton; Stephen Chanock; Montserrat Garcia-Closas
Journal:  Gynecol Oncol       Date:  2010-11-20       Impact factor: 5.482

View more
  3 in total

Review 1.  Genetic alterations and clinical dimensions of oral cancer: a review.

Authors:  Keerthana Karunakaran; Rajiniraja Muniyan
Journal:  Mol Biol Rep       Date:  2020-10-21       Impact factor: 2.316

2.  The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.

Authors:  Xiang Li; Ruishan Zhang; Zhuangkai Liu; Shuang Li; Hong Xu
Journal:  Oncotarget       Date:  2017-03-21

3.  Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients.

Authors:  Francesca Morgese; Davide Soldato; Silvia Pagliaretta; Riccardo Giampieri; Donatella Brancorsini; Mariangela Torniai; Silvia Rinaldi; Agnese Savini; Azzurra Onofri; Marina Scarpelli; Rossana Berardi
Journal:  Oncotarget       Date:  2017-05-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.